AR046789A1 - Inhibidores de fosfodiesterasa 4, que incluyen analogos de diarilamina n-sustituidos - Google Patents

Inhibidores de fosfodiesterasa 4, que incluyen analogos de diarilamina n-sustituidos

Info

Publication number
AR046789A1
AR046789A1 ARP040104598A ARP040104598A AR046789A1 AR 046789 A1 AR046789 A1 AR 046789A1 AR P040104598 A ARP040104598 A AR P040104598A AR P040104598 A ARP040104598 A AR P040104598A AR 046789 A1 AR046789 A1 AR 046789A1
Authority
AR
Argentina
Prior art keywords
alkyl
halogen
substituted
combinations
cyano
Prior art date
Application number
ARP040104598A
Other languages
English (en)
Original Assignee
Memory Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memory Pharm Corp filed Critical Memory Pharm Corp
Publication of AR046789A1 publication Critical patent/AR046789A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/60—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in meta- or para- positions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Se logra la inhibición de la PDE4 utilizando compuestos, por ejemplo, análogos de diarilamina N-sustituidos. Reivindicación 1: Un compuesto de fórmula (1), donde A, B y D son cada uno N o CR5 donde al menos uno de A, B y D es N; R1 es halógeno, alquilo C1-4, alquilo halogenado C1-4, OR6, COR6, CONR6, o NR6COR10; R2 es halógeno, alquilo C1-4, alquilo halogenado C1-4 (por ejemplo, CH2F; CHF2, CF3), OR7, COR6, CONR6, o NR6COR10; R3 es alquilo C1-8 que es de cadena lineal o ramificada y que es insustituido o sustituido una o más veces por halógeno, ciano, alcoxi C1-4, o combinaciones de los mismos, un grupo alquilo carbocíclico parcialmente insaturado donde la porción carbocíclica tiene entre 5 y 14 átomos de C y la porción alquilo que es de cadena lineal o ramificada tiene entre 1 y 5 átomos de C, y que está insustituida, sustituida en la porción carbocíclica una o más veces por halógeno, alquilo, alcoxi, nitro, ciano, oxo, o combinaciones de los mismos, y/o sustituida en la porción alquilo una o más veces por halógeno, alcoxi C1-4, ciano o combinaciones de los mismos, arilalquilo con entre 7 y 19 átomos de C, donde la porción arilo tiene entre 6 y 14 átomos de C y la porción alquilo, que es de cadena lineal o ramificada, tiene entre 1 y 5 átomos de C, donde el radical arilalquilo es insustituido o sustituido, en la porción arilo, una o más veces por halógeno, trifluorometilo, CF3O, nitro, amino, alquilo, alcoxi, amino, alquilamino, dialquilamino, o combinaciones de los mismos, y/o sustituido en la porción alquilo por halógeno, ciano, alquilo C1-4, o combinaciones de los mismos, donde en la porción alquilo uno o más grupos -CH2CH2- se reemplazan cada uno optativamente por -CH=CH- o -C/C-, y/o uno o más grupos -CH2- se reemplazan cada uno optativamente por -O- o -NH-, o grupo heteroarilalquilo, donde la porción heteroarilo puede ser parcial o totalmente saturada y tiene entre 5 y 10 átomos en el anillo en donde al menos 1 átomo del anillo es un N, N-O, O o S, la porción alquilo, que es de cadena lineal o ramificada, tiene entre 1 y 5 átomos de C, el grupo heteroarilalquilo es insustituido, sustituido una o más veces en la porción heteroarilo por halógeno, alquilo, alcoxi, ciano, trifluorometilo, CF3O, nitro, oxo, amino, alquilamino, dialquilamino, o combinaciones de los mismos, y/o sustituido en la porción alquilo una o más veces por halógeno, ciano, alquilo C1-4, o combinaciones de los mismos, R4 es cicloalquilo C3-10, que es insustituido o sustituido una o más veces por halógeno, hidroxi, oxo, ciano, alquilo C1-4, alcoxi C1-4, o combinaciones de los mismos, arilo C6-14 y que es insustituido o sustituido una o más veces por halógeno, alquilo, alquenilo, alquinilo, hidroxi, alcoxi, alcoxialcoxi, nitro, metilendioxi, etilendioxi, trifluorometilo, OCF3, amino, aminoalquilo, aminoalcoxi, dialquilamino, hidroxialquilo, ácido hidroxámico, pirrolilo, tetrazol-5-ilo, 2-(-heterociclo)tetrazol-5-ilo, hidroxialcoxi, carboxi, alcoxicarbonilo, ciano, acilo, alquiltio, alquilsulfinilo, alquilsulfonilo, fenoxi, trialquilsililoxi, R8-L-, o combinaciones de los mismos; heteroarilo C5-10 en el anillo en donde al menos 1 átomo del anillo es un heteroátomo, que es insustituido o sustituido una o más veces por halógeno, alquilo, hidroxi, alcoxi, alcoxialcoxi, nitro, metilendioxi, etilendioxi, trifluorometilo, amino, aminometilo, aminoalquilo, aminoalcoxi, dialquilamino, hidroxialquilo, ácido hidroxámico, tetrazol-5-ilo, hidroxialcoxi, carboxi, alcoxicarbonilo, ciano, acilo, alquiltio, alquilsulfinilo, alquilsulfonilo, fenoxi, trialquilsililoxi, R8-L-, o combinaciones de los mismos, un grupo heterocíclico, que es saturado o parcialmente saturado, con entre 5 y 10 átomos en el anillo en donde al menos 1 átomo del anillo es un átomo de N, O o S, que es insustituido o sustituido una o más veces por halógeno, alquilo, hidroxi, alcoxi, alcoxialcoxi, nitro, oxo, metilendioxi, etilendioxi, trifluorometilo, OCF3, amino, aminometilo, aminoalquilo, aminoalcoxi, dialquilamino, hidroxialquilo, ácido hidroxámico, tetrazol-5-ilo, hidroxialcoxi, carboxi, alcoxicarbonilo, ciano, acilo, alquiltio, alquilsulfinilo, alquilsulfonilo, fenilsulfonilo, fenoxi, cicloalquilo, arilo, heteroarilo o combinaciones de los mismos, un grupo alquilo heterocíclico, donde la porción heterocíclica es saturada, parcialmente saturada o insaturada, y tiene entre 5 y 10 átomos en el anillo en donde al menos 1 átomo del anillo es un átomo de N, O o S, y la porción alquilo es de cadena lineal o ramificada y tiene entre 1 y 5 átomos de C, el grupo alquilo heterocíclico es insustituido, sustituido una o más veces en la porción heterocíclica por halógeno, alquilo, hidroxi, alcoxi, alcoxialcoxi, nitro, oxo, metilendioxi, etilendioxi, trifluorometilo, OCF3, amino, aminometilo, aminoalquilo, aminoalcoxi, dialquilamino, hidroxialquilo, ácido hidroxámico, tetrazol-5-ilo, hidroxialcoxi, carboxi, alcoxicarbonilo, ciano, acilo, alquiltio, alquilsulfinilo, alquilsulfonilo, fenilsulfonilo, fenoxi, cicloalquilo, arilo, heteroarilo o combinaciones de los mismos, y/o sustituida en la porción alquilo una o más veces por halógeno, oxo, hidroxi, ciano, o combinaciones de los mismos, y donde en la porción alquilo uno o más grupos -CH2CH2- se reemplazan cada uno optativamente por -CH=CH- o -C/C-, y uno o más grupos -CH2- se reemplazan cada uno optativamente por -O- o -NH; R5 es H, halógeno, alquilo C1- 4, alcoxi C1-4, o alquilo halogenado C1-4, alcoxi C1-4 o aloxi halogenado C1-4 ; R6 es H o alquilo C1-4, que es de cadena lineal o ramificada y que es insustituido o sustituido una o más veces por halógeno; R7 es H o alquilo C1-12 que es de cadena lineal o ramificada y que es insustituido o sustituido una o más veces por halógeno, hidroxi, ciano, alcoxi C1-4, oxo o combinaciones de los mismos, y donde optativamente uno o más grupos -CH2CH2- se reemplaza en cada caso por -CH=CH- o -C/C-, cicloalquilo C3-10 que es insustituido o sustituido una o más veces por halógeno, hidroxi, oxo, ciano, alquilo C1-4, alcoxi C1-4, o combinaciones de los mismos, cicloalquilalquilo C4-16 que es insustituido o sustituido en la porción cicloalquilo y/o la porción alquilo una o más veces por halógeno, oxo, ciano, hidroxi, alquilo C1-4, alcoxi C1-4 o combinaciones de los mismos; arilo C6-14 y que es insustituido o sustituido una o más veces por halógeno, CF3, OCF3, alquilo, hidroxi, alcoxi, nitro, metilendioxi, etilendioxi, ciano, o combinaciones de los mismos(por ejemplo metilfenilo, metoxifenilo, clorofenilo, etc); arilalquilo en donde la porción arilo tiene entre 6 y 14 átomos de C y la porción alquilo, que es de cadena lineal o ramificada, tiene entre 1 y 5 átomos de C, donde el radical arilalquilo es insustituido, sustituido, en la porción arilo una o más veces por halógeno, CF3, OCF3, alquilo, hidroxi, alcoxi, nitro, ciano, metilendioxi, etilendioxi, o combinaciones de los mismos, y/o sustituida en la porción alquilo una o más veces por halógeno, oxo, hidroxi, ciano, o combinaciones de los mismos, y donde en la porción alquilo uno o más grupos -CH2CH2- se reemplazan cada uno optativamente por -CH=CH- o -C/C-, y uno o más grupos -CH2-se reemplazan cada uno optativamente por -O- o -NH- , un grupo carbocíclico parcialmente insaturado con entre 5 y 14 átomos de C, que es insustituido o sustituido una o más veces por halógeno, alquilo, alcoxi, hidroxi, nitro, ciano, oxo, o combinaciones de los mismos, un grupo heterocíclico, que es saturado, parcialmente saturado o insaturado, con entre 5 y 10 átomos en el anillo en donde al menos 1 átomo del anillo es un átomo de N, O o S, que es insustituido o sustituido una o más veces por halógeno, hidroxi, arilo, alquilo, alcoxi, ciano, trifluorometilo, nitro, oxo, o combinaciones de los mismos, o un grupo alquilo heterocíclico, donde la porción heterocíclica es saturada, parcialmente saturada o insaturada, y tiene entre 5 y 10 átomos en el anillo en donde al menos 1 átomo del anillo es un átomo de N, O o S, y la porción alquilo es de cadena lineal o ramificada y tiene entre 1 y 5 átomos de C, el grupo alquilo heterocíclico es insustituido, sustituido una o más veces en la porción heterocíclica por halógeno, OCF3, hidroxi, arilo, alquilo, alcoxi, ciano, trifluorometilo, nitro, oxo, o combinaciones de los mismos, y/o sustituida en la porción alquilo una o más veces por halógeno, oxo, hidroxi, ciano, o combinaciones de los mismos, y donde en la porción alquilo uno o más grupos -CH2CH2- se reemplazan cada uno optativamente por -CH=CH- o -C/C-, y uno o más grupos -CH2- se reemplazan cada uno optativamente por -O- o -NH-; R8 es H, alquilo C1-8 que es insustituido o sustituido una o más veces por halógeno, alquilo C1-4, alcoxi C1-4, oxo, o combinaciones de los mismos, alquilamino o dialquilamino donde cada porción alquilo tiene en forma independiente entre 1 y 8; un grupo alquilo carbocíclico parcialmente insaturado donde la porción carbocíclica tiene entre 5 y 14 átomos de C y la porción alquilo tiene entre 1 y 5 átomos de C, y que es insustituido o sustituido una o más veces por halógeno, alquilo, alcoxi, nitro, ciano, oxo, o combinaciones de los mismos, cicloalquilo C3-10 que es insustituido o sustituido una o más veces por halógeno, hidroxi, oxo, ciano, alcoxi, alquilo C1-4, o combinaciones de los mismos, cicloalquilalquilo C4-16 que es insustituido o sustituido en la porción cicloalquilo y/o la porción alquilo una o más veces por halógeno, oxo, ciano, hidroxi, alquilo, alcoxi o combinaciones de los mismos, arilo C6-14 que es insustituido o sustituido una o más veces por halógeno, alquilo, hidroxi, alcoxi, alcoxialcoxi, nitro, metilendioxi, etilendioxi, trifluorometilo, amino, aminometilo, aminoalquilo, aminoalcoxi, dialquilamino, hidroxialquilo, ácido hidroxámico, tetrazol-5-ilo, hidroxialcoxi, carboxi, alcoxicarbonilo, ciano, acilo, alquiltio, alquilsulfinilo, alquilsulfonilo, fenoxi, cicloalquilo, arilo, heteroarilo o combinaciones de los mismos; arilalquilo C7-19, donde la porci
ARP040104598A 2003-12-11 2004-12-09 Inhibidores de fosfodiesterasa 4, que incluyen analogos de diarilamina n-sustituidos AR046789A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52848603P 2003-12-11 2003-12-11

Publications (1)

Publication Number Publication Date
AR046789A1 true AR046789A1 (es) 2005-12-21

Family

ID=34710083

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040104598A AR046789A1 (es) 2003-12-11 2004-12-09 Inhibidores de fosfodiesterasa 4, que incluyen analogos de diarilamina n-sustituidos

Country Status (16)

Country Link
US (1) US20050222207A1 (es)
EP (1) EP1692109B1 (es)
JP (1) JP2007513957A (es)
KR (1) KR20060128909A (es)
CN (1) CN1922144A (es)
AR (1) AR046789A1 (es)
AT (1) ATE478049T1 (es)
AU (1) AU2004303855A1 (es)
BR (1) BRPI0417110A (es)
CA (1) CA2548824A1 (es)
DE (1) DE602004028754D1 (es)
MX (1) MXPA06006557A (es)
MY (1) MY141255A (es)
RU (1) RU2388750C2 (es)
TW (1) TW200602322A (es)
WO (1) WO2005061458A2 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030149052A1 (en) * 2002-01-22 2003-08-07 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
ATE421505T1 (de) 2002-07-19 2009-02-15 Memory Pharmaceutical Corp 4-aminobenzofuranverbindungen als phosphodiesterase-4-inhibitoren
EP1534286B1 (en) 2002-07-29 2009-12-09 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
DK1656372T3 (da) 2003-07-30 2013-07-01 Rigel Pharmaceuticals Inc 2,4-pyrimidindiaminforbindelser til anvendelse til behandling eller forebyggelse af autoimmunsygdomme
CA2591948C (en) 2005-01-19 2013-11-12 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
JP5225079B2 (ja) 2005-06-08 2013-07-03 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｊａｋ経路の阻害のための組成物および方法
WO2006135828A2 (en) * 2005-06-10 2006-12-21 Memory Pharmaceuticals Corporation Trisubstituted amines as phosphodiesterase 4 inhibitors
WO2007048846A1 (de) * 2005-10-27 2007-05-03 Neuraxo Biopharmaceuticals Gmbh Verwendung von eisen chelatisierenden verbindungen, zyklisches adenosinmonophosphat erhöhende verbindungen oder kombinationen davon zur behandlung von axonalen läsionen im zns
EP2218442A1 (en) 2005-11-09 2010-08-18 CombinatoRx, Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
CA2640608A1 (en) * 2006-02-01 2007-08-09 Merck & Co., Inc. Potassium channel inhibitors
EP1991532B1 (en) 2006-02-24 2017-01-11 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
ES2945732T3 (es) * 2006-12-22 2023-07-06 Hoffmann La Roche Dispositivo para el suministro mantenido de un líquido terapéutico
ES2544482T3 (es) * 2007-02-27 2015-08-31 National University Corporation Okayama University Compuesto rexinoide que tiene un grupo alcoxi
WO2008127975A2 (en) * 2007-04-11 2008-10-23 Alcon Research, Ltd. Use of an inhibitor of tnfa plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
NZ581127A (en) * 2007-05-25 2012-06-29 Abbott Gmbh & Co Kg Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mglu2 receptor)
EP2070913A1 (en) 2007-12-14 2009-06-17 CHIESI FARMACEUTICI S.p.A. Ester derivatives as phosphodiesterase inhibitors
EP2110375A1 (en) 2008-04-14 2009-10-21 CHIESI FARMACEUTICI S.p.A. Phosphodiesterase-4 inhibitors belonging to the tertiary amine class
MX2010012703A (es) 2008-05-21 2010-12-21 Ariad Pharma Inc Derivados fosforosos como inhibidores de cinasa.
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
WO2010003084A2 (en) * 2008-07-02 2010-01-07 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
WO2010041449A1 (ja) * 2008-10-09 2010-04-15 国立大学法人 岡山大学 Rxr作動性物質を有効成分とする抗アレルギー剤
TW201022192A (en) * 2008-11-04 2010-06-16 Herbalscience Group Llc Tryptase enzyme inhibiting aminothiophenols
JP5721722B2 (ja) * 2009-10-01 2015-05-20 アルコン リサーチ， リミテッド オロパタジン組成物およびその使用
AU2012250517B2 (en) 2011-05-04 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
JP6169492B2 (ja) 2011-11-15 2017-07-26 武田薬品工業株式会社 ジヒドロキシ芳香族へテロ環化合物
AU2013204563B2 (en) 2012-05-05 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
US9273033B2 (en) 2012-11-20 2016-03-01 Merck Sharp & Dohme Corp. Substituted pyridone derivatives as PDE10 inhibitors
GB201222711D0 (en) 2012-12-17 2013-01-30 Takeda Pharmaceutical Novel compounds
SG11201504709PA (en) 2013-03-14 2015-07-30 Dart Neuroscience Llc Substituted pyridine and pyrazine compounds as pde4 inhibitors
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
ES2888074T3 (es) 2013-08-16 2021-12-30 Univ Maastricht Tratamiento del deterioro cognitivo con inhibidor de PDE4
CA3124670A1 (en) 2018-12-28 2020-07-02 Regeneron Pharmaceuticals, Inc. Treatment of respiratory disorders with arachidonate 15-lipoxygenase (alox15) inhibitors

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3259623A (en) * 1963-06-14 1966-07-05 Olin Mathieson Process for preparing 2-(secondary amino)-halogenopyrimidines
GB1337389A (en) * 1969-12-10 1973-11-14 Ici Ltd Pyrimidine derivatives
ZA865090B (en) * 1985-07-22 1988-02-24 Riker Laboratories Inc Substituted di-t-butylphenols
JPH01118957A (ja) 1987-10-31 1989-05-11 Sharp Corp 販売管理装置
GB9311281D0 (en) * 1993-06-01 1993-07-21 Rhone Poulenc Rorer Ltd Novel composition of matter
US5935978A (en) 1991-01-28 1999-08-10 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
US5698711A (en) * 1991-01-28 1997-12-16 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
US6096768A (en) * 1992-01-28 2000-08-01 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
TW229142B (es) * 1992-04-15 1994-09-01 Nissan Detrochem Corp
AU670949B2 (en) 1992-06-15 1996-08-08 Celltech Limited Trisubstituted phenyl derivatives as selective phosphodiesterase IV inhibitors
US5679696A (en) * 1992-07-28 1997-10-21 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic-or heteroatom-containing linking group
US5814651A (en) * 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
US5622977A (en) * 1992-12-23 1997-04-22 Celltech Therapeutics Limited Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same
TW263495B (es) 1992-12-23 1995-11-21 Celltech Ltd
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
CN1046939C (zh) * 1993-07-02 1999-12-01 比克·古尔顿·劳姆贝尔格化学公司 氟烷氧基取代的苯甲酰胺类及其制备方法和应用
CA2174080A1 (en) * 1993-10-12 1995-04-20 Paul Edward Aldrich 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
DE69433594T2 (de) * 1993-12-22 2004-08-05 Celltech R&D Ltd., Slough Trisubstituierte phenyl-derivate, verfahren zu deren herstellung und deren verwendung als phosphodiesterase (typ iv) hemmstoffe
GB9326600D0 (en) * 1993-12-22 1994-03-02 Celltech Ltd Chemical compounds
GB9401460D0 (en) 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
US6245774B1 (en) * 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
US5786354A (en) * 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
GB9412573D0 (en) * 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412571D0 (en) * 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412672D0 (en) * 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
US5591776A (en) * 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
PT813525E (pt) * 1995-03-10 2004-02-27 Berlex Lab Derivados de benzamidina e sua utilizacao como anticoagulantes
WO1996036611A1 (en) * 1995-05-19 1996-11-21 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
FR2735777B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
US5710170A (en) * 1995-12-15 1998-01-20 Merck Frosst Canada, Inc. Tri-aryl ethane derivatives as PDE IV inhibitors
GB9603723D0 (en) * 1996-02-22 1996-04-24 Merck & Co Inc Diphenyl pyridyl derivatives as pde iv inhibitors
GB9526246D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526243D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526245D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
TR199802685T2 (xx) * 1996-06-25 1999-03-22 Pfizer Inc �kameli/katk�l� indazol t�revleri
JPH1072415A (ja) 1996-06-26 1998-03-17 Nikken Chem Co Ltd ３−アニリノ−２−シクロアルケノン誘導体
IL128642A0 (en) * 1996-09-04 2000-01-31 Pfizer Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)
GB9622386D0 (en) 1996-10-28 1997-01-08 Sandoz Ltd Organic compounds
GB9625184D0 (en) * 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds
DE19705012A1 (de) * 1997-02-11 1998-08-13 Hoechst Schering Agrevo Gmbh Herbizide 3-Arylamino-6-trifluormethyluracile
CA2295106C (en) * 1997-06-24 2007-03-13 Nikken Chemicals Co., Ltd. 3-anilino-2-cycloalkenone derivatives
US5919937A (en) * 1997-10-29 1999-07-06 Merck & Co., Inc. Process for phosphodiesterase IV inhibitors
CA2299399C (en) * 1997-11-25 2004-04-06 Warner-Lambert Company Benzenesulfonamide inhibitors of pde-iv and their therapeutic use
AU764005B2 (en) * 1999-02-25 2003-08-07 Merck Frosst Canada & Co. PDE IV inhibiting compounds, compositions and methods of treatment
US6180650B1 (en) * 1999-04-23 2001-01-30 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE 4 inhibitors
US6200993B1 (en) * 1999-05-05 2001-03-13 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE4 inhibitors
AU5020400A (en) * 1999-05-20 2000-12-12 E.I. Du Pont De Nemours And Company Heteroaryloxypyrimidine insecticides and acaricides
US6699890B2 (en) * 2000-12-22 2004-03-02 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
WO2002074726A2 (en) * 2001-01-22 2002-09-26 Memory Pharmaceuticals Corporation Aniline derivatives useful as phosphodiesterase 4 inhibitors
FR2827288B1 (fr) * 2001-07-12 2003-10-31 Servier Lab Nouveaux derives d'octahydro-2h-pyrido[1,2-a]pyrazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20030149052A1 (en) * 2002-01-22 2003-08-07 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
AU2003220935A1 (en) * 2002-04-03 2003-10-13 Sumitomo Pharmaceuticals Company, Limited. Benzamide derivatives
AU2003256616B2 (en) * 2002-07-19 2009-08-27 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs
JP2006508987A (ja) * 2002-11-19 2006-03-16 メモリー・ファーマシューティカルズ・コーポレイション ホスホジエステラーゼ４阻害剤

Also Published As

Publication number Publication date
EP1692109A2 (en) 2006-08-23
MY141255A (en) 2010-03-31
DE602004028754D1 (de) 2010-09-30
US20050222207A1 (en) 2005-10-06
CA2548824A1 (en) 2005-07-07
AU2004303855A1 (en) 2005-07-07
WO2005061458A3 (en) 2005-10-13
JP2007513957A (ja) 2007-05-31
RU2006124518A (ru) 2008-01-27
WO2005061458A2 (en) 2005-07-07
RU2388750C2 (ru) 2010-05-10
KR20060128909A (ko) 2006-12-14
EP1692109B1 (en) 2010-08-18
MXPA06006557A (es) 2007-04-16
CN1922144A (zh) 2007-02-28
BRPI0417110A (pt) 2007-02-06
TW200602322A (en) 2006-01-16
ATE478049T1 (de) 2010-09-15

Similar Documents

Publication Publication Date Title
AR046789A1 (es) Inhibidores de fosfodiesterasa 4, que incluyen analogos de diarilamina n-sustituidos
AR048641A1 (es) Compuestos de aril- o heteroarilamida ortosustituidos utiles como antago-nistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicame
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
EA200870117A1 (ru) Азаиндоловые ингибиторы аурора-киназ
PE20031012A1 (es) Compuesto inhibidor de la hepatitis c
ECSP066721A (es) Inhibidores novedosos de quimasa
PE20070321A1 (es) Compuestos heterociclicos como inhibidores de proteasas
NO20091889L (no) Inhibitorer av spiroketon acetyl-CoA karboksylase
CO5601013A2 (es) Compuestos que modulan la actividad de ppar
CY1106132T1 (el) Παραγωγα πιπepιδινης ως αναστολεις καναλιου καλιου
EA200700363A1 (ru) Фосфонатные аналоги соединений ингибиторов вич
AR055592A1 (es) Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace)
PE20090042A1 (es) Analogos de ciclopamina
EA200601273A1 (ru) Новая кристаллическая форма v агомелатина, способ её получения и фармацевтические композиции, которые её содержат
EA200300763A1 (ru) Пиридиновые ингибиторы матриксных металлопротеиназ
EA200601274A1 (ru) Новая кристаллическая форма iii агомелатина, способ её получения и фармацевтические композиции, которые её содержат
EA200601007A1 (ru) 7-фенилалкилзамещённые 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза)полимеразы
CO5601012A2 (es) Compuestos que modulan la actividad de ppar
NO20092372L (no) Substituerte acetofenoner anvendelige som PDE4-inhibitorer
EA200500201A1 (ru) Новый способ синтеза (7-метокси-1-нафтил)ацетонитрила и его применение при синтезе агомелатина
EA200700758A1 (ru) Новые производные бис-азаиндолов, их получение и фармацевтическое применение в качестве ингибиторов киназ
NO20050871L (no) 6-amino-1H-indazol- og 4-aminobenzofuranforbindelser som fosfodiesterase 4-inhibitorer
DE60330758D1 (de) Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen
PE20021083A1 (es) Moduladores de los receptores estrogenos
DK1373220T3 (da) Benzimidazoler, som er nyttige ved behandling af seksuel dysfunktion

Legal Events

Date Code Title Description
FA Abandonment or withdrawal